Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
197 hedge funds and large institutions have $2.01B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2019 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 84 increasing their positions, 38 reducing their positions, and 34 closing their positions.
167% more call options, than puts
Call options by funds: $162M | Put options by funds: $60.6M
121% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 38
88% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 34
16% more funds holding
Funds holding: 170 → 197 (+27)
2% more capital invested
Capital invested by funds: $1.98B → $2.01B (+$30.1M)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$78.5M |
| 2 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$61.5M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$49.9M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$42.7M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$36.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$64.4M |
| 2 |
SC
Samlyn Capital
New York
|
-$37.5M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$36.4M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$26M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$23.3M |
BHVN Hedge Fund Activity: Q2 2019 in Review
197 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2019, worth a combined $2.01B — up 1.5% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new BHVN positions and 34 closed out — a net gain of 30 holders — while 84 added to existing stakes and 38 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $78.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $64.4M sold.
- 197 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2019, up from 170 in Q1 2019.
- Funds reported $2.01B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2019, up 1.5% quarter-over-quarter.
- 64 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2019 and 34 closed out, a net change of +30 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2019 was Capital International Investors, an estimated $78.5M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2019 was Janus Henderson Group, an estimated $64.4M sold.
Based on aggregated 13F filings for Q2 2019.